Equillium, Inc. Form 8-K Summary
Business Context and Reporting Period
Equillium, Inc. filed a Form 8-K reporting the results of its annual meeting of stockholders held on May 26, 2021. The report was signed and filed on May 28, 2021. The company is a Delaware corporation whose common stock trades on the Nasdaq Global Select Market under the symbol EQ.
Meeting Participation and Voting Results
- As of the April 1, 2021 record date, 29,040,270 common shares were outstanding and entitled to vote.
- Shares present in person or by proxy totaled 24,310,147, representing approximately 83.71% of outstanding shares.
- Daniel M. Bradbury, Martha J. Demski, and Mark Pruzanski, M.D. were each elected as directors. The filing states that the nominees would serve three-year terms expiring at the 2024 annual meeting.
- KPMG LLP was ratified as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.
| Proposal | For | Against or Withheld | Abstentions | Broker Non-Votes |
|---|---|---|---|---|
| Daniel M. Bradbury | 14,661,923.66 | 3,581,415.74 withheld | Not separately stated | 6,066,808.00 |
| Martha J. Demski | 14,661,415.01 | 3,581,924.39 withheld | Not separately stated | 6,066,808.00 |
| Mark Pruzanski, M.D. | 14,667,052.01 | 3,576,287.39 withheld | Not separately stated | 6,066,808.00 |
| KPMG LLP ratification | 24,004,612.40 | 300,425.00 | 5,110.00 | 0.00 |
Financial Metrics and Material Period Changes
This filing does not report revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other operating and financial metrics. It also does not describe material changes versus a prior comparable period.
Outlook, Risks, and Unusual Items
No management outlook, risk update, contingency, or unusual financial item was disclosed. The filing text states that the company is an emerging growth company.
Investor Verification Items
- Verify the director-election disclosure: the filing refers to two Class III director seats but lists three nominees, all of whom it states were elected.
- Confirm the treatment of withheld votes and any unstated abstentions in the director vote table.
- Review subsequent filings for the company’s financial condition, cash runway, clinical-program updates, and any changes to its board or auditor.